STOCK TITAN
  1. Home
  2. Sec-filings
  3. BGMS
  4. [Form 4] Bio Green Med Solution, Inc. Insider Trading Activity

Bio Green Med insider receives 467,535 shares via warrant exchange

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bio Green Med Solution (BGMS) insider filed a Form 4 reporting a warrant-for-share exchange. On November 5, 2025, the reporting person acquired 467,535 shares of Common Stock (transaction code J) at $0 per share under a warrant exchange agreement.

The exchange covered 218,000 Series A warrants at $7.65, 218,000 Series B warrants at $9, and 31,535 Series C warrants at $10.2, each originally exercisable from 06/20/2025 and expiring on 06/20/2030. Following the transaction, the reporting person held 467,535 Common Stock directly and 0 derivative securities.

Positive

  • None.

Negative

  • None.
Insider Kua Khai Loon
Role 10% Owner
Type Security Shares Price Value
Other Series A Common Stock Warrants 218,000 $0.00 --
Other Series B Common Stock Warrants 218,000 $0.00 --
Other Series C Common Stock Warrants 31,535 $0.00 --
Other Common Stock 467,535 $0.00 --
Holdings After Transaction: Series A Common Stock Warrants — 0 shares (Direct); Series B Common Stock Warrants — 0 shares (Direct); Series C Common Stock Warrants — 0 shares (Direct); Common Stock — 467,535 shares (Direct)
Footnotes (1)
  1. [object Object]
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kua Khai Loon
(Last) (First) (Middle)
NO 28 JALAN EKOFLORA
1/13 TAMAN EKOFLORA
(Street)
JOHOR BAHRU N8 81100
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Bio Green Med Solution, Inc. [ BGMS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/05/2025 J(1) 467,535 A $0 467,535 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Common Stock Warrants $7.65 11/05/2025 J(1) 218,000 06/20/2025 06/20/2030 Common Stock 218,000 $0 0 D
Series B Common Stock Warrants $9 11/05/2025 J(1) 218,000 06/20/2025 06/20/2030 Common Stock 218,000 $0 0 D
Series C Common Stock Warrants $10.2 11/05/2025 J(1) 31,535 06/20/2025 06/20/2030 Common Stock 31,535 $0 0 D
Explanation of Responses:
1. Reporting Person exchanged 218,000 Series A Common Stock Purchase Warrants, 218,000 Series B Common Stock Purchase Warrants and 31,535 Series C Common Stock Purchase Warrants for 467,535 shares of Common Stock pursuant to a warrant exchange agreement dated November 5, 2025.
/s/ Kua Khai Loon 11/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did BGMS report in this Form 4 filing?

A warrant exchange where the reporting person received 467,535 Common Stock for warrants under a warrant exchange agreement dated November 5, 2025.

How many BGMS shares were acquired and at what price?

The reporting person acquired 467,535 Common Stock at $0 per share as part of an exchange (code J), not an open-market purchase.

Which warrants were exchanged by the BGMS insider?

Exchanged 218,000 Series A ($7.65), 218,000 Series B ($9), and 31,535 Series C ($10.2) warrants, all originally exercisable 06/20/2025 and expiring 06/20/2030.

What are the insider’s BGMS holdings after the transaction?

Post-exchange, the insider holds 467,535 shares of Common Stock directly and 0 derivative securities.

What was the transaction code and date for BGMS?

Transaction code J on 11/05/2025, reflecting a warrant-for-share exchange pursuant to an agreement.

Was cash paid in this BGMS transaction?

No cash price was reported; the shares were received at $0 as part of the exchange.